Cover Page

Articles in Press

Past Issues

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Editorial Commentary 
The dry retina paradox: interpreting MERLIN in clinical practice
Lasse J. Cehofski, Yousif Subhi
AME Clinical Trials Review  
2026;
4:
31
.
 (25 June 2026) 
PDF Full Text (50) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2
Mariem Galuia, Mark A. Socinski
AME Clinical Trials Review  
2026;
4:
30
.
 (25 June 2026) 
PDF Full Text (357) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon
Joshua R. Niska, Nathan Y. Yu, Jean-Claude M. Rwigema, Sarah E. James, Brady S. Laughlin, Carlos E. Vargas, Steven E. Schild
AME Clinical Trials Review  
2026;
4:
29
.
 (25 June 2026) 
PDF Full Text (73) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer
Keli Santos-Parker, Laura Esserman
AME Clinical Trials Review  
2026;
4:
28
.
 (25 June 2026) 
PDF Full Text (50) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Precision in practice: a new standard in early-relapsing HR+ breast cancer
Nathalie LeVasseur, Karen A. Gelmon
AME Clinical Trials Review  
2026;
4:
27
.
 (25 June 2026) 
PDF Full Text (50) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006)
Federico Monaca, Igor Gómez-Randulfe, Raffaele Califano
AME Clinical Trials Review  
2026;
4:
26
.
 (25 June 2026) 
PDF Full Text (49) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer
Mali Barbi, Divya Bhana, Veena S. John
AME Clinical Trials Review  
2026;
4:
25
.
 (25 June 2026) 
PDF Full Text (51) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?
Takahiro Karasaki
AME Clinical Trials Review  
2026;
4:
24
.
 (25 June 2026) 
PDF Full Text (247) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study
Alessandra Merlini, Paolo Bironzo
AME Clinical Trials Review  
2026;
4:
23
.
 (25 June 2026) 
PDF Full Text (48) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Extensive-stage small cell lung cancer: progress, slowly but surely
Ojbindra KC, Apar Kishor Ganti
AME Clinical Trials Review  
2026;
4:
22
.
 (25 June 2026) 
PDF Full Text (46) Peer Review File COI Form Open Access Get Permission
Letter to the Editor 
Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
Michael Wang, Jutta K. Neuenburg, Constantine S. Tam
AME Clinical Trials Review  
2026;
4:
21
.
 (25 April 2026) 
PDF Full Text (182) COI Form Open Access Get Permission
Letter to the Editor 
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
Frida Bugge Askeland, Fredrik Schjesvold
AME Clinical Trials Review  
2026;
4:
20
.
 (25 April 2026) 
PDF Full Text (140) COI Form Open Access Get Permission
Editorial Commentary 
Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward
Carlos Henrique Barrios, Tomás Reinert
AME Clinical Trials Review  
2026;
4:
19
.
 (25 April 2026) 
PDF Full Text (215) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?
Alice Cattelani, Isabella Frigerio
AME Clinical Trials Review  
2026;
4:
18
.
 (25 April 2026) 
PDF Full Text (148) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Current and around-the-corner therapies in platinum-resistant ovarian cancer: an insight into the ROSELLA study
Valentina Tuninetti, Giorgio Valabrega
AME Clinical Trials Review  
2026;
4:
17
.
 (25 April 2026) 
PDF Full Text (145) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Cachexia, cytokines, and caution: lessons from tocilizumab in advanced pancreatic ductal adenocarcinoma
Carolyn Moloney-Lineen, Devalingam Mahalingam
AME Clinical Trials Review  
2026;
4:
16
.
 (25 April 2026) 
PDF Full Text (210) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
Daniel K. Reef, Natalie Grover
AME Clinical Trials Review  
2026;
4:
15
.
 (25 April 2026) 
PDF Full Text (504) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Not so fast—should neoadjuvant chemotherapy be routine in resectable pancreatic cancers?
Coyin Oh, Devalingam Mahalingam
AME Clinical Trials Review  
2026;
4:
14
.
 (25 April 2026) 
PDF Full Text (462) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Steroid-limited isatuximab-based quadruplet therapy in elderly, transplant-ineligible multiple myeloma: a REST trial commentary
Dennis D. Lee, Faith E. Davies
AME Clinical Trials Review  
2026;
4:
13
.
 (25 April 2026) 
PDF Full Text (237) Peer Review File COI Form Open Access Get Permission
Review Article 
A literature review and reflection on clinical trials: current challenges, future directions, and potential strategies to overcome practical barriers
Kaiping Zhang, Savvas Lampridis, Charles B. Simone II, Ionut Negoi, Yan Peng, Binghan Shang, Yao Lin, Yaling Cheng, Fanghui Yang, Vishal G. Shelat, Kamyar Kalantar-Zadeh
AME Clinical Trials Review  
2026;
4:
12
.
 (25 April 2026) 
PDF Full Text (347) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Currently no content available!
Editorial Commentary 
KEYNOTE-189 5-years update: setting a backbone for the next generation clinical research in advanced non-squamous non-small cell lung cancer without oncogenic addiction
Alessandra Merlini, Anis Cipi, Giorgia Ferrari, Paolo Bironzo
Published online: 11 June 2024
PDF Full Text (19119) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer
Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu
Published online: 15 August 2024
PDF Full Text (16914) Peer Review File COI Form Open Access Get Permission
Review Article 
First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer
Malak Alharbi, Nour Nassour, Vaishali Deenadayalan, Grace K. Dy
Published online: 26 September 2025
PDF Full Text (13002) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)
Yuji Uehara, Aaron C. Tan
Published online: 06 June 2024
PDF Full Text (12643) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Yes to adjuvant osimertinib therapy in EGFR-mutated stage IB–IIIA non-small cell lung cancer post resection, but for how long? (ADAURA/NCT02511106)
Faustine Luo, Sai-Hong Ignatius Ou, Misako Nagasaka
Published online: 21 June 2024
PDF Full Text (12691) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Assessing the UNICANCER-PRODIGE 23 trial through the lens of nonoperative management
Wini Zambare, Aron Bercz, J. Joshua Smith
Published online: 13 May 2025
PDF Full Text (12468) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial
Eva Versteijne, Geertjan van Tienhoven, Anna M. E. Bruynzeel, Johanna W. Wilmink, Marc G. Besselink, Bas Groot Koerkamp; on behalf of the Dutch Pancreatic Cancer Group
Published online: 20 December 2024
PDF Full Text (11261) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer
Faustine X. Luo, Zhaohui Liao Arter, Sai-Hong Ignatius Ou, Misako Nagasaka
Published online: 04 December 2024
PDF Full Text (10935) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?
Anuja Abhyankar, Grace K. Dy
Published online: 21 August 2024
PDF Full Text (10452) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer
Luis Guilherme de Oliveira Silva, Fabian Fellipe Bueno Lemos, Fabrício Freire de Melo
Published online: 08 May 2025
PDF Full Text (10066) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial
Saurav Verma, Jacques Raphael
Published online: 02 September 2024
PDF Full Text (9386) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Immunotherapy as the new standard of care for advanced endometrial cancer
Giovanna Vieira Giannecchini, Martina Parenza Arenhardt, Andreia Cristina de Melo
Published online: 03 April 2025
PDF Full Text (9197) Peer Review File COI Form Open Access Get Permission
Review Article 
Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review
Angelo Pirozzi, Celine Hoyek, Naohiro Okano, Leticia Assad Maia Sandoval, Binbin Zheng-Lin, Oluseyi Abidoye, Cody Eslinger, Mohamad Bassam Sonbol, Mitesh J. Borad, Tanios S. Bekaii-Saab
Published online: 26 September 2025
PDF Full Text (8951) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?
John M. Flack
Published online: 24 February 2025
PDF Full Text (8603) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Post-CDK4/6i wars in HR+/HER2− breast cancer: is elacestrant a solid contender through the lens of precision oncology
Ünal Metin Tokat, Nalan Babacan, Mutlu Demiray
Published online: 01 July 2025
PDF Full Text (8374) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial
Hayley Nicole Roberts, Corinne Maurice-Dror, Kim Nguyen Chi
Published online: 21 February 2025
PDF Full Text (8269) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?
Daniela Damiani, Mario Tiribelli
Published online: 20 June 2024
PDF Full Text (8088) Peer Review File COI Form Open Access Get Permission
Review Article 
The role of minimal residual disease measurement in multiple myeloma
Bhavesh Mohan Lal, Nikhil Vojjala, Nikhila Sampath Kumar, Carolina Schinke
Published online: 26 September 2025
PDF Full Text (7650) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Optimizing antiplatelet therapy after coronary artery bypass graft: selection, dosing, and duration
Lokeswara Rao Sajja, Pradeep Narayan, Sanjeeth Peter
Published online: 17 December 2024
PDF Full Text (7681) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Patritumab deruxtecan: advancing the treatment landscape for EGFR-resistant non-small cell lung cancer
Claudia Parisi, David Planchard, Fabrice Barlesi
Published online: 18 March 2025
PDF Full Text (7309) Peer Review File COI Form Open Access Get Permission

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>

Clinical Trials Education Channel

The Clinical Trials Education Channel aims to publish Review Article of high educational value that can guide the better understanding and practice of the whole cycle of clinical trials, including ethics, methodological design, analysis, reporting, appraisal, and supervision. More >>

Reviewers more

In 2025, ACTR reviewers continue to make outstanding contributions to the peer review process. More >>

Announcement more

ACTR Annual Report 2025

Greetings from Dr. Kaiping Zhang and the Editorial Office of AME Clinical Trials Review (ACTR). More >>

Join us at the 9th World Congress of Pediatric Cardiology & Cardiac Surgery

The 9th World Congress of Pediatric Cardiology & Cardiac Surgery (WCPCCS) is going to be held at the Hong Kong Convention and Exhibition Centre, Hong Kong, China from December 7 to... More >>

AME and Wolters Kluwer aim to expand access to global medical research through new collaboration

The agreement broadens the reach of nearly 50 Open Access titles, contributing globally to over 5,000 articles More >>

Indexing

AME Clinical Trials Review is indexed and covered by

Membership

Member since 2021

Publishing Information

AME Clinical Trials Review is published by AME Publishing Company

AME Publishing Company

AME Clinical Trials Review is published with support from Wolters Kluwer

Wolters Kluwer

Social Media